Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A Phase 2 study of sequential administration of gilteritinib after MEC chemotherapy in Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia in adults: Japan adult leukemia study group (JALSG) RR-FLT3-AML220 study

View Full Paper
Ask AI
Bookmark
Share

Authors

YIYuichi IshikawaTYTakahiro YamauchiTTTomomi Toubai

Discussion

Loading...

Member takes

Overview

Phase 2 trial reports 48.8% complete remission in relapsed/refractory acute myeloid leukemia, suggesting effective sequential treatment with gilteritinib and chemotherapy.

Key Points

  • Gilteritinib following MEC chemotherapy achieved a 48.8% complete remission rate in patients with acute myeloid leukemia.
  • Among 41 patients, the median overall survival reached 32.2 months, indicating improved long-term outcomes.
  • Observational analysis of adverse events showed that 97.6% of patients experienced toxicity, mainly anemia and neutropenia.
  • Findings suggest that the combination treatment may be well tolerated in patients undergoing subsequent transplantation.

Cite This Study

Ishikawa et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e398https://doi.org/10.1182/blood-2025-998
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients2025 · 1 citations
  2. 2Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapsed/refractory FLT3-mutated acute myeloid leukemia: A Japanese nationwide registry study2025
  3. 3Gilteritinib in FLT3‐mutated acute myeloid leukemia: A real‐world Italian experience2025 · 6 citations
  4. 4Efficacy of the triplet therapy with venetoclax, azacitidine and gilteritinib for the treatment of FLT3-ITD mutated AML patients with refractory/relapsed disease or persistent minimal residual disease bridging to allogeneic hematopoietic stem cell transplantation2025 · 2 citations
  5. 5Gilteritinib maintenance therapy after allogeneic hematopoietic stem cell transplantation in FLT3-mutated AML: A systematic review and meta-analysis2025